Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

OncoImmunology

Volumn 4, Issue 5, 2015, Pages

  Vigneron, Nathalie ^a,b,c   van Baren, Nicolas ^a,c   Van den Eynde, Benoît J ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology (Welbio)   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

Dendritic cells; Immunohistochemistry; Immunosuppression; Indoleamine 2, 3 dioxygenase; Tryptophan; Tumor

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2, 3 DIOXYGENASE; MONOCLONAL ANTIBODY; TRYPTOPHAN; TRYPTOPHAN 2, 3 DIOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; DENDRITIC CELL; DRUG TARGETING; ENDOTHELIUM CELL; FEEDBACK SYSTEM; FEMALE GENITAL SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; LUNG ALVEOLUS CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR MICROENVIRONMENT; VALIDATION PROCESS;

EID: 84944463096     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.1003012     Document Type: Article

References (10)

1. Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 2015; 3(2):161-72; PMID: 25271151; http://dx.doi. org/10.1158/2326-6066.CIR-14-0137
2. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722-35; PMID:22822050; http://dx.doi.org/10.1158/2159-8290.CD-12-0014
3. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, BallHJ, Thomas SR, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16:279-85; PMID:20190767; http://dx.doi.org/ 10.1038/nm.2092
4. Lee JR, Dalton RR,Messina JL, SharmaMD, SmithDM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83:1457-66; PMID:14563947; http://dx.doi.org/ 10.1097/01.LAB.0000090158.68852.D1
5. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3; PMID:24829760; http://dx.doi.org/10.1186/2051-1426-2-3.
6. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http:// dx.doi.org/10.1126/scitranslmed.3003689.
7. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi. org/10.1038/nature13954.
8. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/ 10.1126/scitranslmed.3006504.
9. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934.
10. Riesenberg R,Weiler C, Spring O, EderM, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Can Res 2007; 13:6993-7002; http://dx.doi.org/10.1158/ 1078-0432.CCR-07-0942.